Advancements in Early Detection and Targeted Therapies for Breast Cancer; A Comprehensive Analysis
DOI:
https://doi.org/10.70818/apjcr.2024.v01i01.04Keywords:
Breast cancer, early detection, targeted therapy, survival rateAbstract
Background: Breast cancer is a leading cause of morbidity and mortality among women worldwide. Early detection and targeted therapies have significantly improved outcomes, yet challenges remain in optimizing these approaches, especially in resource-limited settings like Rajshahi Medical College Hospital. Objective: This study aims to evaluate the advancements in early detection and targeted therapies for breast cancer, assessing their effectiveness and impact on patient outcomes at Rajshahi Medical College Hospital. Method: A retrospective analysis was conducted on 216 breast cancer patients treated at Rajshahi Medical College Hospital from June 2021 to June 2022. Data were collected on demographic characteristics, diagnostic methods, treatment regimens, and outcomes. The study focused on the use of advanced imaging techniques, liquid biopsies, and targeted therapies, including hormone receptor modulators and HER2-targeted treatments. Statistical analysis was performed to evaluate the efficacy of these interventions. Result: A total 216 patients, 68% were diagnosed at early stages (Stage I or II) due to advanced imaging and diagnostic tools. Targeted therapies were administered to 57% of the patients, with a significant reduction in disease progression observed in 74% of those treated with HER2-targeted therapies. Overall, the one-year survival rate was 89%, with a notable improvement in quality of life. Conclusions: The integration of advanced diagnostic tools and targeted therapies has substantially improved early detection rates and patient outcomes at Rajshahi Medical College Hospital. These findings underscore the importance of continued investment in modern technologies for breast cancer management in resource-limited settings.
References
1. Zubair, M., Wang, S., & Ali, N. (2021). Advanced approaches to breast cancer classification and diagnosis. Frontiers in Pharmacology, 11, 632079.
2. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
3. Wolf, A., Oeffinger, K. C., Shih, T. Y. C., Walter, L. C., Church, T. R., Fontham, E. T., ... & Smith, R. A. (2022). Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA: A Cancer Journal for Clinicians.
4. Ho, P. J., Bok, C. M., Ishak, H. M. M., Lim, L. Y., Liu, J., Wong, F. Y., ... & Li, J. (2019). Factors associated with false-positive mammography at first screen in an Asian population. PLoS One, 14(3), e0213615.
5. Madani, M., Behzadi, M. M., & Nabavi, S. (2022). The role of deep learning in advancing breast cancer detection using different imaging modalities: a systematic review. Cancers, 14(21), 5334.
6. Sardanelli, F., & Podo, F. (2020). Primary Studies on Breast MRI Screening of High-Risk Women. Breast MRI for High-risk Screening, 131-151.
7. Fabisiewicz, A., Szostakowska-Rodzos, M., Zaczek, A. J., & Grzybowska, E. A. (2020). Circulating tumor cells in early and advanced breast cancer; biology and prognostic value. International Journal of Molecular Sciences, 21(5), 1671.
8. McDonald, B. R., Contente-Cuomo, T., Sammut, S. J., Odenheimer-Bergman, A., Ernst, B., Perdigones, N., ... & Murtaza, M. (2019). Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Science translational medicine, 11(504), eaax7392.
9. Pineda Moncusí, M. (2020). Epidemiological study of aromatase inhibitors in women diagnosed with breast cancer: evaluation and management of secondary effects.
10. Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., ... & Cristofanilli, M. (2019). Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor–positive metastatic breast cancer. Journal of Clinical Oncology, 37(14), 1169-1178.
11. Batista, J. D. A. L., Alves, R. J. V., Cardoso, T. B., Moreno, M., Tiscoski, K. A., & Polanczyk, C. A. (2022). Effectiveness of adjuvant trastuzumab in women with HER-2+ breast cancer in the SUS. Ciência & Saúde Coletiva, 28, 1819-1830.
12. Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., ... & Emens, L. A. (2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The lancet oncology, 21(1), 44-59.
13. Bhushan, A., Gonsalves, A., & Menon, J. U. (2021). Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics, 13(5), 723.
14. Biswas, B., Chowdhury, A. S., Akter, S., Fatema, K., Reem, C. S. A., Tuhin, E., & Hasan, H. (2022). Knowledge and attitude about COVID-19 and importance of diet: A cross-sectional study among Bangladeshi people. Bangladesh Journal of Food and Nutrition, 1(1), 04-12.
15. Aktar, S., Akter, K., Akther, K., Begum, S., Islam, T., & Hasan, H. (2022). Knowledge Regarding the Prevention of Cervical Cancer of Adolescent Girls at Rajshahi Division.
16. Kuhl, C. K. (2022). Abbreviated Breast MRI: State of the Art. Radiology, 310(3), e221822.
17. Saad, E. D., Squifflet, P., Burzykowski, T., Quinaux, E., Delaloge, S., Mavroudis, D., ... & Buyse, M. (2019). Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. The Lancet Oncology, 20(3), 361-370.
18. Schlam, I., Tarantino, P., & Tolaney, S. M. (2022). Overcoming resistance to HER2-directed therapies in breast cancer. Cancers, 14(16), 3996.
19. Swain, S. M., Miles, D., Kim, S. B., Im, Y. H., Im, S. A., Semiglazov, V., ... & Patel, T. (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. The Lancet Oncology, 21(4), 519-530.
20. Akinyemiju, T., Oyekunle, T., Salako, O., Gupta, A., Alatise, O., Ogun, G., ... & Daramola, A. (2022). Metabolic syndrome and risk of breast cancer by molecular subtype: analysis of the MEND study. Clinical breast cancer, 22(4), e463-e472.
21. Pace, L. E., & Keating, N. L. (2021). Should women at lower-than-average risk of breast cancer undergo less frequent screening?. JNCI: Journal of the National Cancer Institute, 113(8), 953-954.
22. Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., ... & Martín, M. (2021). Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Cancer Research and Treatment, 187, 467-476.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Asia Pacific Journal of Cancer Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
